All the funding deals in the cell therapy market
Download our beautiful pitch about the cell therapy market
In our cell therapy market deck, you will find everything you need to understand the market
The cell therapy market is attracting steady funding because cell-based medicines are moving from research labs into real clinical and commercial use.
We conducted deep research and collected 58 funding deals in the cell therapy market covering the period from 2024 to 2026.
We refresh this page very often so readers can follow the latest funding activity in the cell therapy market.
And if you want to better understand this new industry, you should get our beautiful slides covering the cell therapy market.
Insights
- The cell therapy market had 58 funding deals in this list, showing that investor interest is spread across oncology, autoimmune disease, neurology, liver disease, and regenerative medicine.
- The largest deal was Autolus Therapeutics at $550.0M, which shows that late-stage CAR-T companies can still attract very large funding rounds.
- CAR-T remains the main funding theme in the cell therapy market, but investors are also backing NK cells, TCR-T, Tregs, iPSC-derived cells, and macrophage therapies.
- In vivo CAR-T is becoming more visible in the cell therapy market, with Umoja Biopharma, Stylus Medicine, Azalea Therapeutics, Vyriad, DeliNova Therapeutics, and MagicRNA Biotech all represented.
- Autoimmune disease is no longer a side theme in the cell therapy market, with Kyverna Therapeutics, Cartesian Therapeutics, Tr1X, Century Therapeutics, and Allogene Therapeutics all raising capital.
- The cell therapy market is not only about cancer. Neurology-focused companies such as Neurona Therapeutics, Kenai Therapeutics, Aspen Neuroscience, BrainStorm Cell Therapeutics, and Regend Therapeutics also raised money.
- Several companies raised money more than once across the period, which suggests that the cell therapy market needs repeated financing as programs move through clinical development.
- Public offerings and private financings both mattered in the cell therapy market, showing that listed companies and private startups are active at the same time.
This chart, featured in our cell therapy market deck, shows annual VC investment in cell therapy startups
Summary table of the funding deals for the cell therapy market since 2024
We define the cell therapy market as the market for cell-based medicinal products used as drugs to treat disease, including both approved products and major late-stage pipeline therapies.
We include living-cell products such as CAR-T, other engineered immune cells, and non-oncology cell-based drugs, along with their direct clinical use and revenue.
We exclude procedures like standard stem-cell transplants, simple minimally manipulated cell preparations used in surgery, and generic tools or equipment that are not specific to these therapies.
We focused exclusively on pure players, defined as companies with at least 70–80% of their business directly tied to the cell therapy market.
Our analysis has been done at a global level with a minimum funding threshold of $300k.
You can also read our detailed analysis to understand how funding activity in the cell therapy market has evolved recently.
If you want a longer-term view, we also have a study of how funding activity in the cell therapy market has changed over the years.
Also, you should know that we have a dedicated page, updated weekly, with all the latest fundraising deals in the cell therapy market.
| Name | What they do | Amount in $ | Quarter | Source(s) |
|---|---|---|---|---|
| Allogene Therapeutics | Develops allogeneic CAR-T therapies for cancer and autoimmune disease. | $200.4M | Q2 2026 | Allogene |
| Lyell Immunopharma | Develops next-generation CAR-T therapies for cancer. | $50.0M | Q1 2026 | FinancialContent |
| BrainStorm Cell Therapeutics | Develops adult stem-cell therapies for neurodegenerative diseases. | $2.0M | Q1 2026 | BrainStorm Cell Therapeutics |
| BioRestorative Therapies | Develops stem-cell therapies and products, including BRTX-100. | $5.0M | Q1 2026 | BioRestorative Therapies |
| Regend Therapeutics | Develops stem and progenitor cell therapies for organ regeneration. | $50.64M | Q1 2026 | Regend Therapeutics |
| Ernexa Therapeutics | Develops iPSC-derived cell therapies for cancer and autoimmune disease. | $10.5M | Q1 2026 | Ernexa Therapeutics |
| OriCell Therapeutics | Develops CAR-T therapies for solid tumors and blood cancers. | $70.0M | Q1 2026 | PR Newswire |
| Cytotheryx | Develops cell-based treatments for liver diseases. | $60.0M | Q1 2026 | PR Newswire |
| Orca Bio | Develops high-precision cell therapies for blood diseases. | $250.0M | Q1 2026 | Orca Bio |
| MEDIPOST | Develops cord-blood stem-cell therapies for degenerative diseases. | $140.0M | Q1 2026 | Business Wire |
| Century Therapeutics | Develops iPSC-derived cell therapies for autoimmune diseases and cancer. | $135.0M | Q1 2026 | Nasdaq |
| Vyriad | Develops in vivo CAR-T therapies using viral-vector delivery. | $25M | Q4 2025 | Business Wire |
| Link Cell Therapies | Develops logic-gated CAR-T therapies for solid and blood cancers. | $60M | Q4 2025 | Link Cell Therapies |
| Pan Cancer T | Develops TCR-T therapies for hard-to-treat solid tumors. | $5.25M | Q4 2025 | Pan Cancer T |
| T-CURX | Develops non-viral CAR-T therapies for AML and solid tumors. | $19.2M | Q4 2025 | New Market Pitch |
| Aspen Neuroscience | Develops personalized iPSC-derived therapies for Parkinson’s disease. | $115M | Q4 2025 | Aspen Neuroscience |
| Captain T Cell | Develops TCR-T cell therapies for solid tumors. | $21.7M | Q4 2025 | Captain T Cell |
| Azalea Therapeutics | Develops in vivo cell engineering, including in vivo CAR-T. | $82M | Q4 2025 | GlobeNewswire |
| Tr1X | Develops engineered Treg therapies for autoimmune and inflammatory diseases. | $50M | Q4 2025 | GlobeNewswire |
| DeliNova Therapeutics | Develops in vivo CAR-T therapies using genetic payload delivery. | $8.3M | Q4 2025 | New Market Pitch |
| iRegene Therapeutics | Develops iPSC-derived cell therapies for Parkinson’s disease. | $40M | Q3 2025 | PR Newswire |
| Wugen | Develops off-the-shelf CAR-T therapies for T-cell malignancies. | $115M | Q3 2025 | Wugen |
| Anocca | Develops gene-edited TCR-T therapies for solid tumors. | $46M | Q3 2025 | Business Wire |
| Dispatch Bio | Combines tumor tagging with engineered immune-cell therapy. | $216M | Q3 2025 | Dispatch Bio |
| NK CellTech | Develops engineered NK-cell therapies for cancer. | $14M | Q3 2025 | New Market Pitch |
| MagicRNA Biotech | Develops mRNA-based in vivo CAR-T therapies. | $14M | Q3 2025 | New Market Pitch |
| A-Seeds | Develops non-viral CAR-T therapies for solid tumors. | $15M | Q3 2025 | New Market Pitch |
| Rui Therapeutics | Develops CAR-NK and universal CAR-T therapies. | $28M | Q3 2025 | New Market Pitch |
| Innovacell | Develops muscle-cell therapies for incontinence and related disorders. | $52M | Q3 2025 | New Market Pitch |
| Stylus Medicine | Develops in vivo genetic medicines, starting with CAR-T. | $85M | Q2 2025 | Business Wire |
| Neurona Therapeutics | Develops neural cell therapies for neurological disorders. | $102M | Q2 2025 | Neurona Therapeutics |
| Garuda Therapeutics | Develops off-the-shelf blood stem-cell therapies. | $50M | Q1 2025 | BioSpace |
| Inceptor Bio | Develops next-generation CAR-T therapies for solid tumors. | $21M | Q1 2025 | Inceptor Bio |
| StemSight | Develops corneal stem-cell therapies for severe blindness. | $2.4M | Q1 2025 | EU-Startups |
| ONGene / ONGeno | Develops bone-marrow stem-cell therapy for multiple sclerosis. | $3.6M | Q1 2025 | New Market Pitch |
| Optieum Biotechnologies | Develops next-generation CAR-T therapies for solid tumors. | $8.6M | Q1 2025 | Zeon |
| Umoja Biopharma | Develops in vivo CAR-T therapies that engineer immune cells. | $100M | Q1 2025 | Umoja Biopharma |
| A2 Biotherapeutics | Develops logic-gated CAR-T therapies using the Tmod platform. | $80M | Q1 2025 | Business Wire |
| HemaCell | Develops iPSC-derived platelet and blood-cell therapies. | $2.8M | Q1 2025 | New Market Pitch |
| March Biosciences | Develops CD5 CAR-T therapy for T-cell lymphoma. | $28.4M | Q4 2024 | BioSpace |
| Be Biopharma | Develops engineered B-cell medicines for genetic diseases. | $82.0M | Q4 2024 | Business Wire |
| AvenCell Therapeutics | Develops switchable universal CAR-T therapies. | $112.0M | Q4 2024 | AvenCell |
| Resolution Therapeutics | Develops engineered macrophage therapy for end-stage liver disease. | $83.0M | Q3 2024 | PR Newswire |
| GC Therapeutics | Develops iPSC-derived off-the-shelf cell therapies. | $75.0M | Q3 2024 | Business Wire |
| ArsenalBio | Develops programmable CAR-T therapies for solid tumors. | $325.0M | Q3 2024 | ArsenalBio |
| Outpace Bio | Develops AI-designed T-cell therapies for solid tumors. | $144.0M | Q3 2024 | Outpace Bio |
| Artiva Biotherapeutics | Develops allogeneic NK-cell therapies for autoimmune disease and cancer. | $167.0M | Q3 2024 | Artiva Biotherapeutics |
| Cartesian Therapeutics | Develops mRNA CAR-T therapies for autoimmune diseases. | $130.0M | Q3 2024 | Selecta Biosciences |
| Century Therapeutics | Develops iPSC-derived NK and T-cell therapies. | $60.0M | Q2 2024 | BioPharma Dive |
| Obsidian Therapeutics | Develops engineered TIL therapies for cancer. | $160.5M | Q2 2024 | Obsidian Therapeutics |
| Nkarta | Develops engineered NK-cell therapies, including NKX019. | $240.1M | Q2 2024 | Nkarta |
| Capstan Therapeutics | Develops in vivo cell reprogramming using RNA delivery. | $175.0M | Q2 2024 | Business Wire |
| Kenai Therapeutics | Develops iPSC-derived neuron replacement therapies. | $82.0M | Q1 2024 | Business Wire |
| Iovance Biotherapeutics | Develops TIL therapies for cancer. | $211.0M | Q1 2024 | DLA Piper |
| Sana Biotechnology | Develops engineered cells, including hypoimmune allogeneic therapies. | $189.75M | Q1 2024 | Wilson Sonsini |
| Kyverna Therapeutics | Develops CD19 CAR-T therapies for autoimmune diseases. | $319.0M | Q1 2024 | Renaissance Capital, BioPharma Dive |
| Autolus Therapeutics | Develops programmed T-cell and CAR-T therapies. | $550.0M | Q1 2024 | Cooley, Syncona |
| Neurona Therapeutics | Develops regenerative cell therapies for neurological disorders. | $120.0M | Q1 2024 | Neurona Therapeutics |
| Tr1X | Develops allogeneic Treg therapies for autoimmune and inflammatory diseases. | $75.0M | Q1 2024 | Tr1X Bio |
This market map, featured in our cell therapy market deck, highlights top companies and startups in the cell therapy market
Related blog posts
- The latest progress in the cell therapy market
- What is the latest news in the cell therapy market?
- What is the true size of the cell therapy market?
- What are the latest funding developments in the cell therapy market?
- What are the key fundraising trends in the cell therapy market?
- How funding activity has evolved in the cell therapy market
